Investing.com - 诺华 (NYSE:NVS) (SIX:NOVN)表示,其实验性抗体ianalumab与eltrombopag联合使用,在针对原发性免疫性血小板减少症(ITP)患者的3期(VAYHIT2)研究中达到了主要目标。 该治疗方案显著延长了治疗失败的时间,测量患者在治疗期间和治疗后维持安全血小板水平的持续时间。 诺华股价在欧洲交易中上涨0.5%。 这家瑞士制药商表示,这项后期...
Source LinkInvesting.com - 诺华 (NYSE:NVS) (SIX:NOVN)表示,其实验性抗体ianalumab与eltrombopag联合使用,在针对原发性免疫性血小板减少症(ITP)患者的3期(VAYHIT2)研究中达到了主要目标。 该治疗方案显著延长了治疗失败的时间,测量患者在治疗期间和治疗后维持安全血小板水平的持续时间。 诺华股价在欧洲交易中上涨0.5%。 这家瑞士制药商表示,这项后期...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.